Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ
J Clin Oncol. 2005 23 (36): 9265-74

PMID: 16361624 · DOI:10.1200/JCO.2005.03.0536

MeSH Terms (18)

Adenocarcinoma Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Agents Colorectal Neoplasms Disease Progression Dose-Response Relationship, Drug Female Gefitinib Humans Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Quinazolines Survival Analysis

Connections (4)

This publication is referenced by other Labnodes entities: